Share on StockTwits

Equities research analysts at N+1 Singer began coverage on shares of Clinigen Group PLC (LON:CLIN) in a research note issued to investors on Thursday. The firm set a “buy” rating and a GBX 439 ($7.39) price target on the stock. N+1 Singer’s target price points to a potential upside of 20.52% from the stock’s previous close.

A number of other firms have also recently commented on CLIN. Analysts at Investec reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. Separately, analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. They now have a GBX 650 ($10.94) price target on the stock. Finally, analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. They now have a GBX 650 ($10.94) price target on the stock.

Shares of Clinigen Group PLC (LON:CLIN) traded down 2.87% during mid-day trading on Thursday, hitting GBX 363.0316. The stock had a trading volume of 266,933 shares. Clinigen Group PLC has a 52-week low of GBX 354.92 and a 52-week high of GBX 690.00. The stock has a 50-day moving average of GBX 380.1 and a 200-day moving average of GBX 482.6.

Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.